Sanofi-aventis and Regeneron Pharmaceuticals, Inc. entered into agreements to expand and extend their existing global collaboration established November 2007, to discover, develop, and commercialize therapeutic monoclonal antibodies. Sanofi-aventis will increase its annual funding from $100million to $160 million beginning in 2010, and the research funding will extend through 2017. The companies plan to advance an average of four to five antibodies into clinical development each year. Sanofi-...